Tickers

1. Composite Trajectory Verdict

Given CDNA's status as a growth-oriented diagnostics company with a history of GAAP losses heavily influenced by non-recurring litigation and divestiture items, the cash flow statement matters most because it reflects the actual liquidity generated from operations to fund ongoing investment, share repurchases, and acquisitions without relying on external financing.

Composite Trajectory: Mixed

The annual income statement shows deterioration, with GAAP net income swinging from a $52.5 million profit in 2024 to a $21.4 million loss in 2025, driven by a $102 million litigation expense swing (10-K 2025-12-31, Consolidated Statements of Operations). Conversely, the quarterly income statement shows sharp improvement, with Q2 2026 net income of $110.6 million versus a $8.6 million loss in Q2 2025, almost entirely due to a $113 million gain on the sale of the lab products business (10-Q 2026-06-30, Consolidated Statements of Operations). Cash generation has improved consistently: annual operating cash flow rose to $42.0 million in 2025 from $38.0 million in 2024, and six-month operating cash flow reached $34.9 million in H1 2026 versus -$16.7 million in H1 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). The balance sheet weakened in 2025 (assets and equity down) but strengthened dramatically by June 30, 2026 due to the divestiture proceeds, though the subsequent Naveris acquisition ($161.8 million) is not yet reflected (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets; 10-Q 2026-06-30, MD&A).

2. Red Flags

• Litigation expense volatility: GAAP operating expenses swung by $102 million year-over-year due to a $96.3 million litigation gain in 2024 reversing to a $5.7 million expense in 2025 (10-K 2025-12-31, Consolidated Statements of Operations).
• Refunds reserve growing: Testing services revenue was reduced by $3.5 million in 2025 for estimated refunds to third-party payers, and by $2.4 million in Q2 2026 and $5.8 million in H1 2026 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Accounts receivable declining sharply: Receivables fell from $64.6 million at year-end 2024 to $42.6 million at year-end 2025, and further to $34.4 million by June 30, 2026, outpacing revenue growth (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets).
• One-time gain dominating quarterly earnings: The $113 million gain on sale of the lab products business accounted for virtually all of Q2 2026 operating income and net income (10-Q 2026-06-30, Consolidated Statements of Operations).
• Large share repurchases while generating losses: The company spent $87.8 million on buybacks in 2025 despite a $21.4 million net loss, and $12.2 million in H1 2026 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Pending acquisition not on balance sheet: The $161.8 million cash acquisition of Naveris closed July 1, 2026, materially altering the pro forma liquidity position (10-Q 2026-06-30, MD&A).
• Valuation allowance on deferred tax assets: A full valuation allowance of $92.6 million offsets nearly all U.S. and Sweden deferred tax assets, indicating limited near-term tax benefit realization (10-K 2025-12-31, Note 12).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Annual GAAP results deteriorated, with net income falling from $52.5 million in 2024 to a -$21.4 million loss in 2025, and operating income swinging from $40.8 million to -$30.8 million (10-K 2025-12-31, Consolidated Statements of Operations). This was primarily driven by a $102 million litigation expense swing (from a $96.3 million gain to a $5.7 million charge) and a 25% increase in sales and marketing expense to $102.6 million (10-K 2025-12-31, Consolidated Statements of Operations). However, quarterly and six-month GAAP results improved dramatically: Q2 2026 net income was $110.6 million versus -$8.6 million in Q2 2025, and H1 2026 net income was $113.4 million versus -$18.9 million in H1 2025 (10-Q 2026-06-30, Consolidated Statements of Operations). This improvement is almost entirely attributable to a $113 million gain on the sale of the lab products business recognized in Q2 2026 (10-Q 2026-06-30, Consolidated Statements of Operations). Revenue growth was strong across all periods: +14% annually, +52% in Q2, and +46% in H1, with testing services volume growing ~14-17% YoY (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). Excluding the litigation swing and divestiture gain, core operating losses appear to be narrowing, but GAAP figures show mixed signals depending on the period and one-time items.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Operating cash flow has increased in each comparable period. Annual operating cash flow rose to $42.0 million in 2025 from $38.0 million in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). For the first six months of 2026, operating cash flow was $34.9 million versus -$16.7 million in H1 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows). The H1 2026 figure includes a $113 million non-cash add-back for the gain on sale; however, changes in operating assets and liabilities were a modest $2.9 million use of cash, and stock-based compensation added back $20.5 million (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Investing cash flow in H1 2026 was $291.6 million, driven by $164.8 million in net proceeds from the lab products sale and $174.3 million in marketable securities maturities/sales (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Financing cash outflows decreased to $18.4 million in H1 2026 from $54.5 million in H1 2025, mainly due to lower share repurchases ($12.2 million vs $50.0 million) (10-Q 2026-06-30, Consolidated Statements of Cash Flows). The company ended June 2026 with $373.6 million in cash and no debt (10-Q 2026-06-30, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: The year-end 2025 balance sheet weakened relative to 2024: total assets fell to $413.2 million from $491.1 million, cash and marketable securities declined to $201.4 million from $260.7 million, and stockholders' equity dropped to $303.1 million from $378.4 million, while the accumulated deficit deepened to -$735.4 million from -$626.2 million (10-K 2025-12-31, Consolidated Balance Sheets). By June 30, 2026, the balance sheet strengthened substantially due to the lab products divestiture: total assets rose to $533.0 million, cash surged to $373.6 million (with marketable securities liquidated to zero), equity increased to $425.6 million, and the accumulated deficit improved to -$505.4 million (10-Q 2026-06-30, Consolidated Balance Sheets). Inventory dropped 74% to $7.0 million as the lab products business was sold (10-Q 2026-06-30, Consolidated Balance Sheets). The July 1, 2026 Naveris acquisition for $161.8 million cash (plus up to $100 million contingent) is not reflected in the June 30 balance sheet (10-Q 2026-06-30, MD&A). Liabilities have remained relatively stable around $110 million across both periods (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly (Q1, Q3, Q4) income statements and cash flow statements for 2025 and 2026 to assess intra-year trends and seasonality.
• Standalone Q2 2026 cash flow statement (only six-month data provided in the 10-Q).
• Detailed breakdown of the $113 million gain on sale (tax impact, working capital adjustments, earnout terms).
• Pro forma balance sheet and cash flow impact of the Naveris acquisition closed July 1, 2026.
• Segment-level profitability (testing services vs. patient/digital vs. products) to assess margin trends by business line.
• Revenue concentration by payer (Medicare ~34% per 10-K) and any changes in reimbursement rates or coverage policies.
• Details on the $12.2 million remaining under the May 2025 repurchase program and the new $100 million April 2026 program.